We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$4.88B
AUM Growth
+$975M
Cap. Flow
+$671M
Cap. Flow %
13.75%
Top 10 Hldgs %
41.91%
Holding
108
New
15
Increased
25
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
SYY icon
Sysco
SYY
+$82.5M
2
LEGN icon
Legend Biotech
LEGN
+$79.9M
3
BHVN icon
Biohaven
BHVN
+$57.8M
4
NOW icon
ServiceNow
NOW
+$47.9M
5
QURE icon
uniQure
QURE
+$47M

Top Sells

Rank Stock Value
1
ETNB
89bio
ETNB
+$122M
2
KDP icon
Keurig Dr Pepper
KDP
+$40.1M
3
FERG icon
Ferguson
FERG
+$35.1M
4
RNAM
Avidity Biosciences
RNAM
+$32.7M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 51.05%
2 Technology 10.74%
3 Consumer Discretionary 6.34%
4 Financials 4.61%
5 Consumer Staples 3.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
76
DexCom
DXCM
$32B
$2.1M 0.04%
31,680
– –
SYK icon
77
Stryker
SYK
$130B
$2.06M 0.04%
5,860
– –
MDLN
78
Medline Inc
MDLN
$30.9B
$1.78M 0.04%
+42,500
New +$1.79M
IQV icon
79
IQVIA
IQV
$39.3B
$1.62M 0.03%
7,175
– –
MCK icon
80
McKesson
MCK
$101B
$1.5M 0.03%
1,830
– –
HCA icon
81
HCA Healthcare
HCA
$89.5B
$1.49M 0.03%
3,190
– –
WAT icon
82
Waters Corp
WAT
$39.9B
$1.2M 0.02%
3,150
– –
EW icon
83
Edwards Lifesciences
EW
$51.7B
$946K 0.02%
11,100
– –
IONS icon
84
Ionis Pharmaceuticals
IONS
$9.4B
$854K 0.02%
10,800
– –
A icon
85
Agilent Technologies
A
$41.2B
$679K 0.01%
4,990
– –
RMD icon
86
ResMed
RMD
$30.7B
$576K 0.01%
2,390
– –
VLTO icon
87
Veralto
VLTO
$24B
$546K 0.01%
5,475
– –
VRDN icon
88
Viridian Therapeutics
VRDN
$2.67B
$520K 0.01%
+16,700
New +$458K
STE icon
89
Steris
STE
$23.1B
$388K 0.01%
1,530
– –
SRPT icon
90
Sarepta Therapeutics
SRPT
$1.77B
$385K 0.01%
17,888
– –
REPL icon
91
Replimune Group
REPL
$1.01B
$350K 0.01%
+36,038
New +$306K
ZBH icon
92
Zimmer Biomet
ZBH
$18.4B
$293K 0.01%
3,260
– –
CRL icon
93
Charles River Laboratories
CRL
$12.8B
$201K ﹤0.01%
+1,010
New +$183K
AVTR icon
94
Avantor
AVTR
$9.19B
– –
-71,850
Closed -$897K
ELAN icon
95
Elanco Animal Health
ELAN
$11.1B
– –
-253,600
Closed -$5.11M
ETNB
96
DELISTED
89bio
ETNB
– –
-8,280,000
Closed -$122M
LKFT
97
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
– –
-37,111
Closed -$1.29M
KDP icon
98
CALL
Keurig Dr Pepper
KDP
$40.8B
– –
-1,000,000
Closed -$25.5M
KDP icon
99
Keurig Dr Pepper
KDP
$40.8B
– –
-1,570,000
Closed -$40.1M
MRK icon
100
Merck
MRK
$318B
– –
-219,178
Closed -$18.4M
1 2 3
4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Suvretta Capital Management held 108 positions worth $4.88B, up 25% from $3.91B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Suvretta Capital Management deployed $671M of net new capital in Q4 2025, opening 15 new positions and adding to 25 existing holdings. Its largest new stake was Sysco: 1,083,790 shares worth $79.9M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 51% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Ferguson, an estimated $35.1M trimmed.

  • Suvretta Capital Management's largest Q4 2025 buy was Sysco: 1,083,790 shares worth $79.9M.
  • Suvretta Capital Management added most to Legend Biotech in Q4 2025, an estimated $79.9M increase.
  • Suvretta Capital Management's biggest Q4 2025 reduction was Ferguson, cutting an estimated $35.1M.
  • Suvretta Capital Management fully exited 89bio in Q4 2025, selling an estimated $122M.
  • Suvretta Capital Management's ten largest holdings make up 42% of its $4.88B portfolio in Q4 2025.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q4 2025.
  • Suvretta Capital Management's portfolio value rose 25% quarter-over-quarter to $4.88B.

Based on Suvretta Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.